Status:
COMPLETED
Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
Lead Sponsor:
Foundation for Liver Research
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether it is possible to augment the response of patients with HBeAg-positive chronic hepatitis B to entecavir by using a temporary peginterferon alpha-2a ...
Eligibility Criteria
Inclusion
- Chronic hepatitis B (HBsAg positive \> 6 months)
- HBeAg positive, anti-HBe negative at screening
- ALT \> 1.3 x ULN within 60 days prior to screening and during screening
- Liver biopsy performed within 2 years prior to screening or during screening
- Age \> 18 years
- Written informed consent
- Adequate contraception for males and females during treatment and follow up; negative pregnancy test (for women of childbearing potential)
Exclusion
- Antiviral therapy against HBV within the previous 6 months
- Treatment with any investigational drug within 30 days of screening
- Previous treatment with lamivudine or telbivudine for more than six months
- Severe hepatitis activity as documented by ALT\>10 x ULN
- History of decompensated cirrhosis (defined as jaundice in the presence of cirrhosis, ascites, bleeding gastric or esophageal varices or encephalopathy)
- Pre-existent neutropenia (neutrophils \< 1,500/mm3) or thrombocytopenia (platelets \< 90,000/mm3)
- Co-infection with hepatitis C virus or human immunodeficiency virus (HIV)
- Other acquired or inherited causes of liver disease (i.e. alcoholic liver disease, obesity induced liver disease, drug related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficiency)
- Alpha fetoprotein \> 50 ng/ml
- Hyper- or hypothyroidism (subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met)
- Immune suppressive treatment within the previous 6 months
- Contra-indications for alpha-interferon therapy like suspected hypersensitivity to interferon or PEG-interferon or any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study.
- Pregnancy, lactation
- Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant)
- Any medical condition requiring, or likely to require chronic systemic administration of steroids, during the course of the study
- Substance abuse, such as alcohol (\> 80 g/day), I.V. drugs and inhaled drugs in the past 2 years.
- Any other condition which in the opinion of the principal investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00877760
Start Date
August 1 2009
End Date
July 1 2013
Last Update
March 28 2014
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital
Shanghai, China
2
Shanghai Public Health Center
Shanghai, China
3
Zhong Shan hospital, Fu Dan University
Shanghai, China
4
Amsterdam Medical Center (AMC)
Amsterdam, Netherlands